Révolutionner la découverte de biomarqueurs grâce à une plateforme immunoprotéomique à haut débit BOSTON, 30 juillet 2024 /PRNewswire/ — Sengenics Corporation LLC est fière d’annoncer le lancement de i-Ome Cancer, un outil de recherche de pointe conçu pour transformer la découverte de…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.